Your session is about to expire
← Back to Search
NG-641 + Nivolumab for Advanced Cancer (NEBULA Trial)
NEBULA Trial Summary
This trial is testing a new drug, NG-641, to see if it is safe and effective when used with another drug, nivolumab, to treat patients with metastatic or advanced epithelial tumors.
NEBULA Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowNEBULA Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.NEBULA Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer has returned or didn't respond to treatment, and there's no standard treatment left.My bone marrow is working well.My liver is working well.I am fully active or can carry out light work.My kidneys are working well.My lungs are functioning well enough for treatment.I have a significant blood clotting disorder.I have at least one tumor that can be measured and is either not in a previously treated area or has grown despite treatment.I have received certain vaccines within a specific timeframe.I haven't had severe bleeding or related hospital visits in the last 6 months.My tumor is in a place where swelling or tissue death would be dangerous.I have had or am planning to have a bone marrow or organ transplant.I have had serious lung conditions not caused by infections.My cancer has spread to my lymph channels.I have had my spleen removed.I haven't had any major heart or blood vessel problems in the last 6 months.I have used specific treatments before.I have an autoimmune disease, am immunocompromised, or take long-term immunosuppressants.I am 18 years old or older.I have a diagnosed eye condition affecting my retina.I have not had bowel infections or inflammation in the last 3 months.I have had severe kidney injury or significant kidney problems in the past.I have a history of hepatitis B or currently have hepatitis C.My tumor can be safely biopsied, and I agree to have it done.I have taken antiviral medication recently.I am currently suffering from severe depression.I haven't had serious infections or fevers needing antibiotics or doctor's care in the last week.
- Group 1: Intravenous
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this trial pioneering a unique course of action?
"Research into the effects of NG-641 paired with Nivolumab has been conducted since Ono Pharmaceutical Co. Ltd.'s 2012 trial, which included 659 participants. Following its Phase 1 & 2 approval, there are currently 717 studies taking place in 2356 cities and 49 countries worldwide."
What clinical indications are being treated with the tandem of NG-641 and Nivolumab?
"NG-641 and Nivolumab are the recommended treatments for malignant neoplasms, but they have also been found to be effective at treating other medical conditions like unresectable melanoma, squamous cell carcinoma, and metastatic esophageal adenocarcinoma."
What is the capacity of participants for this clinical experiment?
"Correct. It is apparent through the data available on clinicaltrials.gov that this medical research, posted initially on December 1st 2021, requires participants for its trial program. The study seeks to enlist 30 volunteers from a solitary clinic location."
Are there still open slots for participants in this clinical experiment?
"Affirmative. Clinicaltrials.gov indicates that this medical trial is currently accepting patients; the posting was first made on December 1st 2021 with a recent edit occurring on March 16th 2022. The research team is hoping to enroll 30 individuals from one particular site."
What potential risks have been linked to the concomitant administration of NG-641 and Nivolumab?
"The safety of NG-641 combined with Nivolumab has been assessed as a 1 due to the scant evidence available, since it is an early Phase 1 trial."
Could you outline the previous experimentation with NG-641 and Nivolumab?
"Currently 717 clinical trials are assessing the efficacy of NG-641 in alliance with Nivolumab, 82 of which have entered Phase 3. While several research centres based in Basel BE are running these investigations, there is a total of 40290 sites studying this combination worldwide."
Share this study with friends
Copy Link
Messenger